UBS Group’s Mural Oncology MURA Stock Holding History

UBS Group’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-445	Closed	-$921	–	10953
2025 Q3	$921	Sell	445 -4,861	-92%	-$10.4K	﹤0.01%	9493
2025 Q2	$13.1K	Sell	5,306 -101,002	-95%	-$238K	﹤0.01%	8709
2025 Q1	$134K	Buy	106,308 +104,372	+5,391%	+$381K	﹤0.01%	6817
2024 Q4	$6.23K	Buy	1,936 +1,251	+183%	+$4.41K	﹤0.01%	8581
2024 Q3	$2.14K	Sell	685 -19,267	-97%	-$62.7K	﹤0.01%	8490
2024 Q2	$62.6K	Sell	19,952 -421	-2%	-$1.55K	﹤0.01%	6514
2024 Q1	$99.6K	Buy	20,373 +7,055	+53%	+$34.2K	﹤0.01%	6230
2023 Q4	$78.8K	Buy	+13,318	New	+$53.5K	﹤0.01%	6312

UBS Group's MURA Position: Q4 2025 in Review

UBS Group sold out of Mural Oncology (MURA) in Q4 2025, closing a stake of 445 shares — an estimated $921 sold.

UBS Group first reported a position in MURA in Q4 2023 and held it in 8 quarters. The position peaked at $134K in Q1 2025. 0 funds tracked by Wall St. Rank hold MURA as of Q4 2025.

UBS Group reported no remaining Mural Oncology position as of Q4 2025 after selling out during the quarter.
UBS Group sold 445 Mural Oncology shares in Q4 2025, an estimated $921.
UBS Group first reported a position in Mural Oncology in Q4 2023 and held it in 8 quarters.
UBS Group's Mural Oncology position peaked at $134K in Q1 2025.
0 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.